Overview
Introduction
Datamonitor estimates that there are 267m people in the seven major markets with total
cholesterol >200mg/dL and this is set to rise to 286m in 2015. The market has been dominated by
statins for a number of years now, however, with updated guidelines taking a more aggressive
approach to treatment, there is a need for more efficacious and safe alternatives on the market.
Scope
- Patient potential for developmental antidyslipidemics over the period 2005-2015
- Insight into the R&D pipeline with detailed information on drugs in development, clinical
trial results and identification of suitable comparators
- Evaluation of key players in the antidyslipidemics market and opposing company approaches to
development and commercialization
- Analysis of key antidyslipidemic drugs in development and their ability to satisfy major unmet
needs and compete with existing agents
Highlights
The NCEP committee updated the guidelines in 2004, taking a more aggressive approach to the
treatment of dyslipidemia to help further reduce cardiovascular risk. This in turn has increased the
need for alternative drugs that can help lower LDL cholesterol to meet the new lower threshold
without putting patients at risk.
The antidyslipidemic R&D pipeline is still relatively young with 91% of drugs in Phase I and
II. There also appears to be a lot of investment in adjunctive therapies with approximately 69% of
the drugs in the pipeline representing this class.
Datamonitor has identified Pfizers atorvastatin + torcetrapib combination drug and Japan
Tobaccos JTT-705 as the most promising drugs in the pipeline. The atorvastatin + torcetrapib
combination target both LDL and HDL with a synergistic effect which means it may offer significant
advantages in efficacy with improved safety.
Reasons to Purchase
- View independent sales forecasts for drugs in late stage development for treatment of
dyslipidemia
- Examine the classes of products in development by phase and the challenges they have to face to
reach the market
- Identify early-stage antidyslipidemic compounds with high potential being developed by companies
seeking a marketing partner
View Cart
